Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. (Q55071119)

17 June 2018

title

Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. (English)

1 reference

17 June 2018

author name string

Kayo Harada-Shirado

1

1 reference

17 June 2018

Kazuhiko Ikeda

2

1 reference

17 June 2018

Kazuei Ogawa

3

1 reference

17 June 2018

Hiroshi Ohkawara

4

1 reference

17 June 2018

Hideo Kimura

5

1 reference

17 June 2018

Tatsuyuki Kai

6

1 reference

17 June 2018

Hideyoshi Noji

7

1 reference

17 June 2018

Soji Morishita

8

1 reference

17 June 2018

Norio Komatsu

9

1 reference

17 June 2018

Yasuchika Takeishi

10

1 reference

17 June 2018

language of work or name

English

0 references

publication date

19 September 2014

1 reference

17 June 2018

British Journal of Haematology

published in

1 reference

17 June 2018

volume

168

1 reference

17 June 2018

issue

3

1 reference

17 June 2018

page(s)

338-349

1 reference

17 June 2018

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias

cites work

1 reference

Efficacy of vorinostat in a murine model of polycythemia vera

21 January 2018

1 reference

Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

21 January 2018

1 reference

Aberrant expression of microRNA in polycythemia vera.

21 January 2018

1 reference

DNA methylation and demethylation in mammals

21 January 2018

1 reference

Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.

21 January 2018

1 reference

The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells

21 January 2018

1 reference

Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis

21 January 2018

1 reference

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

21 January 2018

1 reference

JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan

21 January 2018

1 reference

Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.

21 January 2018

1 reference

Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene

21 January 2018

1 reference

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells

21 January 2018

1 reference

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

21 January 2018

1 reference

Roles of HMGA proteins in cancer

21 January 2018

1 reference

Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).

21 January 2018

1 reference

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice

21 January 2018

1 reference

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.

21 January 2018

1 reference

Somatic mutations of calreticulin in myeloproliferative neoplasms

21 January 2018

1 reference

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

The tumor suppressor microRNA let-7 represses the HMGA2 oncogene

21 January 2018

1 reference

Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging

21 January 2018

1 reference

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia

21 January 2018

1 reference

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).

21 January 2018

1 reference

Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation

21 January 2018

1 reference

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

21 January 2018

1 reference

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders

21 January 2018

1 reference

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

21 January 2018

1 reference

Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression

21 January 2018

1 reference

A network of heterochronic genes including Imp1 regulates temporal changes in stem cell properties

21 January 2018

1 reference

Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies.

21 January 2018

1 reference

Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes

21 January 2018

1 reference

Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer

21 January 2018

1 reference

The role of mutations in epigenetic regulators in myeloid malignancies

21 January 2018

1 reference

HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis.

21 January 2018

1 reference

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

21 January 2018

1 reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

21 January 2018

1 reference

Oncogenic HMGA2: short or small?

21 January 2018

1 reference

MicroRNAs in myeloproliferative neoplasms

21 January 2018

1 reference

Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.13129

1 reference

17 June 2018

PubMed ID

25236537

1 reference

17 June 2018